Loading
Every dated change on the records linked to Anal cancer (squamous cell carcinoma), newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Screening with anal cytology / high-resolution anoscopy and treatment of HSIL (ablation, topical therapy) reduces progression to cancer by 57% (ANCHOR).
Progression to anal cancer 173 per 100,000 person-years with treatment against 402 with active monitoring, a 57 percent reduction (95% CI 6 to 80, p 0.
A milestone in how this cancer is treated.
Response rate 57 percent with cisplatin-fluorouracil against 59 percent with carboplatin-paclitaxel; serious adverse events 62 against 36 percent; median overall survival 12.
A milestone in how this cancer is treated.
Prevention of premalignant genital lesions, cervical cancer and genital warts from age 9 (Gardasil); anal lesions and cancer added later
Prevention of cervical, vulvar and vaginal cancers and precancers and genital warts caused by HPV 6, 11, 16 and 18 in females 9 to 26 (males 2009; anal cancer 2010); superseded by Gardasil 9